TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes

BACKGROUND: TLR9 agonists are being developed as immunotherapy against malignancies and infections. TLR9 is primarily expressed in B cells and plasmacytoid dendritic cells (pDCs). TLR9 signalling may be critically important for B cell activity in lymph nodes but little is known about the in vivo imp...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:EBioMedicine
Κύριοι συγγραφείς: Schleimann, Mariane H., Kobberø, Maria-Louise, Vibholm, Line K., Kjær, Kathrine, Giron, Leila B., Busman-Sahay, Kathleen, Chan, Chi Ngai, Nekorchuk, Michael, Schmidt, Manuel, Wittig, Burghardt, Damsgaard, Tine E., Ahlburg, Peter, Hellfritzsch, Michel B., Zuwala, Kaja, Rothemejer, Frederik H., Olesen, Rikke, Schommers, Phillipp, Klein, Florian, Dweep, Harsh, Kossenkov, Andrew, Nyengaard, Jens R., Estes, Jacob D., Abdel-Mohsen, Mohamed, Østergaard, Lars, Tolstrup, Martin, Søgaard, Ole S., Denton, Paul W.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Elsevier 2019
Θέματα:
Research paper
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6642412/
https://ncbi.nlm.nih.gov/pubmed/31300344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.07.005
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια